Skip to main content
NeuroThera Labs Inc. logo

NeuroThera Labs Inc. — Investor Relations & Filings

Ticker · NTLX ISIN · CA64136J1012 LEI · 529900GPL3C0DVADMS32 TSXV Manufacturing
Open in API
Filings indexed 145 across all filing types
Latest filing 2025-11-08 Proxy Solicitation & In…
Country CA Canada
Listing TSXV NTLX

About NeuroThera Labs Inc.

https://www.neurothera.com/

NeuroThera Labs Inc. is a clinical-stage company specializing in the development of therapeutics and advanced technologies for central nervous system (CNS) disorders and brain health. The company operates through two primary development streams. First, it is a leader in photobiomodulation (PBM) technology, developing drug-free, non-invasive devices for neurotherapy, targeting conditions such as Major Depressive Disorder (MDD), Alzheimer’s Disease, and Traumatic Brain Injury (TBI). Second, NeuroThera maintains a pharmaceutical pipeline focused on novel drug candidates, including programs based on THC and proprietary opioid/non-opioid compounds designed to enhance pain relief and treat CNS disorders. This dual approach leverages both advanced medical devices and clinical-stage drug candidates to address prevalent neurological conditions.

Recent filings

Filing Released Lang Actions
Notice of the meeting and record date - English.pdf
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a formal notice from a transfer agent (Endeavor Trust) to regulators regarding an upcoming 'Annual General & Special Meeting' for NeuroThera Labs Inc. It specifies record dates, meeting dates, and proxy-related material distribution instructions. This type of document is a standard precursor to a shareholder meeting, typically categorized as a Proxy Solicitation & Information Statement (PSI) or a regulatory notice regarding meeting logistics.
2025-11-08 English
Notice (amended).pdf
Regulatory Filings
2025-11-06 English
Report of exempt distribution (45-106F1).pdf
Regulatory Filings
2025-10-30 English
Material change report - English.pdf
M&A Activity Classification · 87% confidence The document is a Form 51-102F3 Material Change Report filed under Canadian securities rules. It describes the closing of an arm’s‐length share sale (asset and share purchase) transaction with SciSparc Ltd., including issuance of shares, warrants and contingent rights, name/symbol change, board changes and escrow arrangements. This is clearly an M&A transaction announcement rather than an earnings release or standalone audit. Thus it best fits the M&A Activity category (Code: TAR).
2025-10-30 English
Notice.pdf
M&A Activity Classification · 90% confidence The document is a detailed announcement of a share and asset purchase transaction under a TSX Venture Exchange qualifying transaction, including the issuance of shares, warrants, contingent rights, corporate name change, and trading symbol change. This fits squarely within M&A Activity (Code: TAR) which covers announcements and documents related to merger proposals or takeover bids.
2025-10-30 English
News release - English.pdf
Regulatory Filings
2025-10-22 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.